Paul Malcharek, MD
Internal Medicine · Maryville, ILNPI 1891781951
Payments from drug & device makers
Across 370 payments — averaging $24.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$4K
- AbbVie$729
- Lilly USA, LLC$691
- AstraZeneca$659
- Amgen$356
- Johnson & Johnson$334
- plus $2K from 31 others
What the payments were for
- Consulting fees$2,10023%
- Travel & lodging$1,24414%
- Food & beverage$5,68363%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 48 | $4,143 |
| AbbVie(2 entities) | 51 | $729 |
| Lilly USA, LLC | 43 | $691 |
| AstraZeneca | 37 | $659 |
| Amgen | 21 | $356 |
| Johnson & Johnson | 26 | $334 |
| GSK | 27 | $332 |
| Novo Nordisk | 25 | $278 |
| Boehringer Ingelheim | 14 | $236 |
| Sanofi-aventis U.S. LLC | 7 | $141 |
| Amarin Pharma, Inc. | 8 | $117 |
| Supernus Pharmaceuticals, Inc. | 7 | $116 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $81 |
| Astellas Pharma US Inc | 4 | $77 |
| Abbott | 4 | $67 |
| Kowa Pharmaceuticals America, Inc. | 4 | $62 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $54 |
| Biohaven Pharmaceuticals, Inc. | 3 | $53 |
| Merck | 4 | $52 |
| Axsome Therapeutics, Inc. | 3 | $48 |
| Exact Sciences | 3 | $48 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $41 |
| Bristol Myers Squibb | 2 | $38 |
| Mannkind Corporation | 3 | $37 |
| E.r. Squibb & Sons, L.L.C. | 2 | $35 |
| Edwards Lifesciences | 1 | $25 |
| Itamar Medical Inc | 1 | $24 |
| GE HealthCare | 1 | $23 |
| Lundbeck LLC | 1 | $21 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| Tris Pharma Inc | 1 | $18 |
| Bayer | 1 | $18 |
| Novartis | 1 | $14 |
| Optos, Inc. | 1 | $13 |
| Eisai Inc. | 1 | $12 |
| Shire North American Group Inc | 1 | $12 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EUCRISA$2,100
How this compares
$9,034 in reported general payments places this provider in the 90th percentile of 5,182 internal medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 102 | $141,329 |
| EliquisApixaban | 93 | $96,289 |
| TrulicityDulaglutide | 67 | $88,016 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 66 | $61,493 |
| JardianceEmpagliflozin | 49 | $58,996 |
| XareltoRivaroxaban | 45 | $42,637 |
| OzempicSemaglutide | 21 | $34,715 |
| FarxigaDapagliflozin Propanediol | 25 | $25,357 |
| OxycontinOxycodone Hcl | 11 | $23,138 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $14,075 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $12,936 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $12,203 |
| TradjentaLinagliptin | 22 | $11,517 |
| JanuviaSitagliptin Phosphate | 18 | $10,268 |
| MyrbetriqMirabegron | 13 | $9,691 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $691 | $229,344169 claims |
| PfizerEliquis, Paxlovid | $4,143 | $100,677111 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $332 | $86,63297 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $236 | $77,13782 claims |
| Johnson & JohnsonXarelto | $334 | $42,63745 claims |
| Novo NordiskOzempic | $278 | $34,71521 claims |
| AstraZenecaFarxiga | $659 | $25,35725 claims |
| MerckJanuvia, Dulera | $52 | $14,14829 claims |
| Astellas Pharma US IncMyrbetriq | $77 | $9,69113 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $18 | $9,17713 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $62 | $3,76112 claims |
| AbbVieSynthroid | $729 | $2,39029 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,182 internal medicine providers in Illinois.
Other internal medicine in Maryville
- Dennis LevinsonChicago$25.3M
- Mary BrownRockford$16M
- Andrew BartlettChampaign$4.1M
- Danny SugimotoChicago$4M
- Peter O DonnellChicago$3.9M
- Daniel CatenacciChicago$3.5M
- Jeffrey GeohasEvanston$2.3M
- Patricia WalshChicago$2.1M
- Merle DiamondChicago$1.7M
- Yoko MomoyamaLombard$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.